Tscan Therapeutics is trading 7.95% up now at $0.36 after no new company-specific announcement was identified for September 18, 2026.
- The move appears tied to broader biotech and risk-on sentiment.
- The latest major update remains the September 2 strategic reorganization.
- The plan prioritized in vivo solid-tumor programs and reduced the workforce by approximately 75%.